You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 27 No. 4, October 1972 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (80)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias

Randi Rubovits, MD; Harold L. Klawans, Jr, MD

Arch Gen Psychiatry. 1972;27(4):502-507.


Abstract

Amphetamine-induced stereotyped behavior in animals and tardive dyskinesias in humans are both related to the activity of dopamine at striatal dopamine receptors. Antichlinergic agents potentiate the stereotyped behavior induced by amphetamines. Anticholinergic agents, as well as prolonged chlorpromazie pretreatment, decrease the threshold for ampheramine-induced stereotyped behavior.

These observations have several implications for tardive dydkinesias in man. Anticholinergic medications should worsen tardive dyskinesias. Anticholinergics may also decrease the threshold for tardive dyskinesias, thereby increasing the incidence of the disorder. Patients who have a subclinical abnormality of the dopaminergic receptors may manifest this movement disorder only when given anticholinergic medication.

It is suggested that patients on long-term neuroleptic therapy not be routinely given anticholinergic agents, since these drugs worsen tardive duskinesias in patients who have this disorder and may increase the incidence of tardive dyskinesias in patients receiving neuroleptics.



Author Affiliations

Chicago

From the Department of Neurological Sciences, Rush Presbyterian-St. Luke's Medical Center, Chicago. Dr. Rubovits is currently with the Department of Psychiatry, University of Maryland, Baltimore.


Footnotes

Accepted for publication May 15, 1972.

Reprint requests to Presbyterian-St. Luke's Hospital, 1753 W Congress Pkwy, Chicago 60612 (Dr. Klawans).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brain {gamma}-Aminobutyric Acid Abnormality in Tardive Dyskinesia: Reduction in Cerebrospinal Fluid GABA Levels and Therapeutic Response to GABA Agonist Treatment
Thaker et al.
Arch Gen Psychiatry 1987;44:522-529.
ABSTRACT  

Kainic acid lesions of the striatum dissociate amphetamine and apomorphine stereotypy: similarities to Huntingdon's chorea
Mason et al.
Science 1978;201:352-355.
ABSTRACT  

Respiratory Dyskinesias: Extrapyramidal Dysfunction and Dyspnea
WEINER et al.
ANN INTERN MED 1978;88:327-331.
ABSTRACT  

A Neuroendocrine Study of Supersensitivity in Tardive Dyskinesia
Tamminga et al.
Arch Gen Psychiatry 1977;34:1199-1203.
ABSTRACT  

Neurological Syndromes Associated With Antipsychotic Drug Use: A Special Report
FREEDMAN
Arch Gen Psychiatry 1973;28:463-467.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1972 American Medical Association. All Rights Reserved.